

## Special Issue

# Hepatitis C Virus: From Discovery to Nobel Prize

### Message from the Guest Editor

The aim of this Special Issue of *Viruses* aims to present up-to-date reviews of different aspects of chronic hepatitis C, after the discovery of hepatitis A virus, hepatitis B virus, hepatitis delta virus, and hepatitis E virus. Their epidemiology, as well as their pathogenesis, have been studied in great detail. The cause of the non-A and non-B post-transfusion hepatitis, however, remained an enigma until the hepatitis C virus was discovered in 1989 by M. Houghton and collaborators, followed by the rapid development of HCV-specific serological and molecular diagnostic assay systems, including HCV genotyping. Our ability to effectively treat chronic viral hepatitis C has resulted in better control of this infection. It is now possible to prevent hepatitis B but not hepatitis C and to cure hepatitis C, with the perspective to meet the World Health Organization goal of elimination of HCV infection by 2030. Unfortunately, there is no vaccine available to date.

### Guest Editor

Prof. Dr. Hubert E. Blum

Department of Medicine, University Medical Center Freiburg, Freiburg, Germany

### Deadline for manuscript submissions

closed (28 February 2023)



## Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/si/113073](https://mdpi.com/si/113073)

*Viruses*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[viruses@mdpi.com](mailto:viruses@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[viruses](https://viruses.mdpi.com)





# Viruses

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.5  
CiteScore 7.7  
Indexed in PubMed



[mdpi.com/journal/  
viruses](https://mdpi.com/journal/viruses)



## About the Journal

### Message from the Editor-in-Chief

*Viruses* (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

---

### Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,  
National Cancer Institute, Frederick, MD 21702-1201, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

#### Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).